Clinical

The approval comes following the review of a phase 2 single-arm trial in 106 patients with chronic lymphocytic leukemia who carried the 17p deletion mutation and who had received at least 1 prior therapy for their condition.

Members of the American Society of Clinical Oncology (ASCO) have articulated concerns regarding the current proliferation of clinical pathways in oncology that could affect patient access and care quality. In response, ASCO established an ad hoc Task Force, which issued a policy statement to guide the future development and implementation of these treatment management tools.

What we're reading, April 11, 2016: UnitedHealth calls it quits for 2 Obamacare state exchanges; study finds disparities across country in lifespans of low-income people; and Hillary Clinton and PhRMA agree on one proposal to curb drug costs.

A prospective longitudinal study that followed terminally ill cancer patients till their death has found that patients of African American origins had a poorer understanding of their survival than the white patients in the study group.

Patient-Centered Diabetes Care (PCDC) is important because it provides a venue to share new knowledge and to meet different stakeholders that impact diabetes care, explained Robert A. Gabbay, MD, PhD, FACP, chief medical officer of the Joslin Diabetes Center, chair of PCDC, and editor-in-chief of Evidence-Based Diabetes Management.

The intravenous acetaminophen Ofirmev has been shown to decrease hospital length of stay, opioid-related complications, and overall costs compared with traditional opioid analgesics.

A new study in behavioral cardiology establishes a strong link between posttraumatic stress disorder and an increased risk for cardiovascular diseases and deaths.

This week in managed care, the top stories included new data on statin prescriptions, a trial found the PCSK9 inhibitor Repatha successfully lowered cholesterol, but an editorial said the price might be too high to be worth it, and Farzad Mostashari, MD, discussed care transformation.

A preliminary briefing document expresses concerns over clinical benefit over existing treatments, safety, and overall risk-benefit of the drug for the subset of lung cancer patients for whom the drug has been developed.

The National Comprehensive Cancer Network (NCCN)'s annual conference has traditionally been a platform for NCCN’s Guideline updates. This year's meeting saw much more, with discussions on palliative care, biosimilars, and value in cancer care.

Drug developer Amgen is questioning the assessment of its multiple myeloma treatments at the hands of the Institute for Clinical and Economic Review.

Patients with grade 2 glial brain tumors (gliomas) who were treated with radiation therapy (RT) and chemotherapy had a longer progression-free survival and overall survival than those who received RT alone.

Intracoronary gene transfer among heart failure patients increased left ventricular function beyond standard heart failure therapy.

What we're reading, April 6, 2016: the federal government could be doing more to alert uninsured individuals about their eligibility for subsidies; the White House will transfer leftover Ebola funds to combat the Zika virus; and Senate companion bill to 21st Century Cures Act is almost done.

In men with low-risk prostate cancer, hypofractionation is non-inferior than the standard treatment dose and has the potential for saving treatment costs, according to a new study in the Journal of Clinical Oncology.

The FDA has approved infliximab-dyyb as a biosimilar and not as an interchangeable biological.

The study, commissioned by the Community Oncology Alliance, has found that overall costs for Medicare and commercial health plan enrollees have been increasing at the same rate as the cost of treating patients with cancer. This contradicts the popular notion that cancer care costs have far outpaced overall healthcare spending.

What we're reading: new rules from the Treasury Department could derail the Pfizer-Allergan merger; false medical beliefs could lead white medical students and residents to suggest inappropriate treatment for black patients; and while prescriptions were down, sales were up for the top 10 drugs in the US.

It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.

Patients with chronic obstructive pulmonary disease (COPD) who engage in greater amounts of physical activity in the 12 months prior to hospitalization for COPD have a lower risk of death in the year following discharge.

A new study by researchers at the Kaiser Permanente Center for Health Research has found that visits by trained community health workers improved screening rates for breast cancer among Latino women.

What we're reading: California will open Medi-Cal to all low-income children regardless of immigration status; Arizona governor signs bill to follow earlier FDA guidelines for abortion-inducing drug; and the loss of 2 Obamacare provisions could result in increased premiums in 2017.

Nearly half of patients at an urban primary care clinic affiliated with a large academic medical center had a diagnosed mental health problem.

John A. Thompson, MD, co-director of the Melanoma Clinic at the Seattle Cancer Care Alliance, highlighted the major points of his melanoma talk at the National Comprehensive Cancer Network’s 21st Annual Meeting, including the FDA approval of new drugs and the development of new viral therapies.

There are a number of lessons oncologists have learned as the population of women who were diagnosed with breast cancer at a younger age grow older, said Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.

While these "generic" biologicals have been deemed to have the potential to create competition and result in healthcare savings-although not to the extent of generic products-technical issues with manufacturing these products have troubled drug manufacturers.

At the National Comprehensive Cancer Network (NCCN) 21st Annual Conference, Alan P. Venook, MD, professor of Clinical Medicine at the University of California, San Francisco, provided insight into lessons learned by oncologists in the treatment of colorectal cancer.

The National Pharmaceutical Council has released a set of guiding principles on specific elements that should be included in value assessment frameworks.

At the National Comprehensive Cancer Network (NCCN)'s 21st Annual Conference, Robert Carlson, MD, chief executive officer, NCCN, provided a flavor for their value framework, the Evidence Blocks.